GRIFOLS ITALY operating for over 15 years in the distribution of plasma-derived products in our country, having already achieved a leading position in the Italian market.
Ethics and quality of service are the main theme of our business in Italy and in the world, since 1940 in the service of health workers and patients users of our drugs.
Our mission is to bring to Italy all Proteins Plasma derivatives produced in large and modern plants of Parets (Spain) and Los Angeles (USA) and in new plants that will soon be added, with continual improvements in yield, purity and safety and introducing those innovative, currently under research and development.
The Group Grifols collects high quality human plasma through its FDA Approved US centers plasmapheresis .
We provide the Hospital Pharmacies systems for the distribution and monitoring of drugs (Kardex), modular cleanrooms (Misterium®), equipment for the preparation of sterile infusion solutions and products for oncology (Gri-fill® 3.0) and equipment single-dose packaging of drugs destined, in hospital administration, at the bedside (Blispack).
We provide blood and plasma centers bags and equipment for transfusion, the MB-VIP service (methylene Blue Virus Inactivated Plasma) and Advanced technologies for inactivation of pathogens (viruses and bacteria) of platelet concentrates as exclusive distributors for Italy Cerus Intercept technology Inc. This technology provides the advantage to the Italian transfusion centers can also be used for virusinattivazione “in house” Plasma distributed transfusion purposes. In addition we provide medicine Transfusion Italian simple systems and efficient traceability of the transfusion of blood and plasma (Gricode®) with the benefit cost / benefit truly competitive
Contact
GRIFOLS ITALIA, S.p.A.
Via Torino, 15
56010 Vicopisano (PI)
ITALY
Tel: +39 050 87 55 111
Fax: +39 050 87 98 84
E-mail: italia@grifols.com
Web: grifols.com
Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on…
Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the…
Ferring Pharmaceuticals’ Federico Gomes de Freitas, General Manager Italy, gives us an overview of how the Italian affiliate fits into the company’s global strategy, especially with respect to reproductive health,…
Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous…
Giorgio Palú, President of the Italian Medicines Agency (AIFA) helps us understand how the agency works, explains the criteria they use to evaluate innovative medicines and tells us about AIFA’s…
Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market. …
SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug…
Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy…
Pierluigi Petrone outlines family-owned Petrone Group’s wide-range of outsourcing services to the pharmaceutical industry, how its international footprint has evolved over time, and his key priorities as president of Italy’s…
Organon Italy’s Alper Alptekin introduces the newly formed women’s health company, his priorities for the Italian affiliate, and how improvements in women’s health can improve gender equality and give women…
Bormioli Pharma’s Andrea Lodetti outlines the company’s evolution towards becoming an international leader in the pharma and primary packaging business, COVID-related business impacts, the shift towards localised manufacturing, and the…
Speaking exclusively to PharmaBoardroom, Pierluigi Antonelli outlines Angelini Pharma’s progress in transforming from a traditional, Italy-focused, and family-owned firm into a true European innovator. Antonelli outlines the potential impact of…
Claudia Coscia outlines how the geographic and portfolio transformation of Kyowa Kirin has played out in Italy in recent years. Coscia also touches on access challenges for rare disease therapies…
See our Cookie Privacy Policy Here
